GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Senti Biosciences Inc (NAS:SNTI) » Definitions » Beneish M-Score

Senti Biosciences (Senti Biosciences) Beneish M-Score : 72.77 (As of May. 25, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Senti Biosciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 72.77 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Senti Biosciences's Beneish M-Score or its related term are showing as below:

SNTI' s Beneish M-Score Range Over the Past 10 Years
Min: -3.27   Med: 40.89   Max: 72.77
Current: 72.77

During the past 4 years, the highest Beneish M-Score of Senti Biosciences was 72.77. The lowest was -3.27. And the median was 40.89.


Senti Biosciences Beneish M-Score Historical Data

The historical data trend for Senti Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senti Biosciences Beneish M-Score Chart

Senti Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Beneish M-Score
- - - 39.34

Senti Biosciences Quarterly Data
Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -3.27 42.44 39.34 72.77

Competitive Comparison of Senti Biosciences's Beneish M-Score

For the Biotechnology subindustry, Senti Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Senti Biosciences's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Senti Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Senti Biosciences's Beneish M-Score falls into.



Senti Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Senti Biosciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 83.4424+0.528 * 1+0.404 * 2.5011+0.892 * 0.2715+0.115 * 0.3679
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 2.8724+4.679 * -0.009561-0.327 * 1.3612
=72.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was $17.92 Mil.
Revenue was 0 + 0 + 0.255 + 0.687 = $0.94 Mil.
Gross Profit was 0 + 0 + 0.255 + 0.687 = $0.94 Mil.
Total Current Assets was $55.67 Mil.
Total Assets was $102.19 Mil.
Property, Plant and Equipment(Net PPE) was $40.15 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.96 Mil.
Selling, General, & Admin. Expense(SGA) was $32.85 Mil.
Total Current Liabilities was $9.61 Mil.
Long-Term Debt & Capital Lease Obligation was $32.45 Mil.
Net Income was -12.111 + -18.716 + -14.923 + -18.697 = $-64.45 Mil.
Non Operating Income was 3.859 + -0.687 + -19.013 + 0.144 = $-15.70 Mil.
Cash Flow from Operations was -11.682 + -7.037 + -15.379 + -13.675 = $-47.77 Mil.
Total Receivables was $0.79 Mil.
Revenue was 1.036 + -0.191 + 1.516 + 1.108 = $3.47 Mil.
Gross Profit was 1.036 + -0.191 + 1.516 + 1.108 = $3.47 Mil.
Total Current Assets was $80.51 Mil.
Total Assets was $161.43 Mil.
Property, Plant and Equipment(Net PPE) was $76.89 Mil.
Depreciation, Depletion and Amortization(DDA) was $3.84 Mil.
Selling, General, & Admin. Expense(SGA) was $42.11 Mil.
Total Current Liabilities was $12.87 Mil.
Long-Term Debt & Capital Lease Obligation was $35.94 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(17.923 / 0.942) / (0.791 / 3.469)
=19.026539 / 0.22802
=83.4424

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.469 / 3.469) / (0.942 / 0.942)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (55.666 + 40.151) / 102.185) / (1 - (80.511 + 76.892) / 161.425)
=0.062318 / 0.024916
=2.5011

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.942 / 3.469
=0.2715

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(3.839 / (3.839 + 76.892)) / (5.961 / (5.961 + 40.151))
=0.047553 / 0.129272
=0.3679

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(32.846 / 0.942) / (42.11 / 3.469)
=34.868365 / 12.138945
=2.8724

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((32.445 + 9.609) / 102.185) / ((35.939 + 12.866) / 161.425)
=0.411548 / 0.302339
=1.3612

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-64.447 - -15.697 - -47.773) / 102.185
=-0.009561

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Senti Biosciences has a M-score of 72.77 signals that the company is likely to be a manipulator.


Senti Biosciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Senti Biosciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Senti Biosciences (Senti Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
2 Corporate Drive, First Floor, South San Francisco, CA, USA, 94080
Senti Biosciences Inc is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.
Executives
Kanya Rajangam officer: Chief Medical & Devt. Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Aktiengesellschaft Bayer 10 percent owner BAYERWERK, GEBAEUDE W11, KAISER-WILHELM-ALLEE, LEVERKUSEN 2M D-51368
Susan D Berland director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Timothy K Lu director, officer: CEO and President SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
James J. Collins director C/O FULCRUM THERAPEUTICS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Bayer World Investments B.v. 10 percent owner ENERGIEWEG 1, MIJDRECHT P7 3641
Deborah Knobelman officer: Chief Financial Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Herberts Curt A. Iii officer: Chief Operating Officer 501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Brenda Cooperstone director C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Philip J Lee officer: Chief Technology Officer C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080
Edward T Mathers director C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093